论文部分内容阅读
目的:观察不稳定型心绞痛(UAP)患者使用2种剂量(10和20mg/d)的阿托伐他汀治疗10d后血脂、高敏C反应蛋白(hsCRP)、基质金属蛋白酶9(MMP9)、一氧化氮(NO)、肌酸激酶(CK)及谷丙转氨酶(ALT)的变化。方法:将临床确诊为UAP的90例患者随机分为:阿托伐他汀治疗组:分别接受10mg/d(32例)和20mg/d(30例)阿托伐他汀治疗;对照组(28例):不接受任何调脂药物治疗;所有对象均测定治疗前和治疗10d后hsCRP、MMP9、NO、ALT、CK和血脂水平的变化。结果:阿托伐他汀治疗组治疗前后比较,血脂、hsCRP、MMP9水平明显下降(P<0.05),与对照组治疗后相比亦明显下降(P<0.05);除hsCRP外,20mg/d较10mg/d治疗后血脂、MMP9水平下降更显著(P<0.05)。20mg/d治疗前后比较,ALT水平显著升高(P<0.05);治疗后2组ALT水平依次升高,且差异有统计学意义(P<0.05)。结论:在UAP早期使用较大剂量(20mg/d)的阿托伐他汀治疗10d,即可明显减轻炎症、调节血脂、稳定斑块。
OBJECTIVE: To observe the changes of plasma lipids, high sensitivity C-reactive protein (hsCRP), matrix metalloproteinase 9 (MMP9), and monoxide after 10 days in patients with unstable angina pectoris (UAP) treated with two doses of atorvastatin (10 and 20 mg / Nitrogen (NO), creatine kinase (CK) and alanine aminotransferase (ALT) were measured. Methods: Ninety patients clinically diagnosed as UAP were randomly divided into two groups: Atorvastatin treatment group received atorvastatin 10 mg / d (32 cases) and 20 mg / d (30 cases) respectively. The control group (28 cases ): Did not receive any lipid-lowering drug therapy; all subjects were measured before and after treatment for 10d hsCRP, MMP9, NO, ALT, CK and blood lipid levels. Results: Compared with the control group, the levels of serum lipids, hsCRP and MMP9 in atorvastatin group were significantly decreased (P <0.05), and the levels of serum lipids, hsCRP and MMP9 in the atorvastatin group were significantly lower than those in the control group After 10 mg / d treatment, the levels of serum lipids and MMP9 decreased more significantly (P <0.05). The level of ALT increased significantly (P <0.05) before and after treatment with 20 mg / d, and the levels of ALT increased in turn after treatment, with statistical significance (P <0.05). Conclusion: At the early stage of UAP, atorvastatin at the higher dose (20mg / d) can reduce inflammation, regulate blood lipid and stabilize the plaque.